JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ — Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Stoboclo (CT-P41, denosumab-bmwo), a biosimilar referencing Prolia (denosumab), for all indications of the…Original Article
FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia
